


CLAIMS

1. A compound represented by the formula (I):



5 wherein

Ring A and Ring B are each independently an optionally further substituted benzene ring,

Ring C is an imidazole ring optionally further substituted by C₁₋₆ alkyl group(s) optionally substituted by 1 to 3

10 substituents selected from

(1) a halogen atom,

(2) a nitro group,

(3) a cyano group,

(4) an amino group,

15 (5) a hydroxy group, and

(6) an optionally halogenated C₁₋₆ alkoxy group,

L is a bond or an optionally substituted methylene group,

R¹ is a hydrogen atom or a substituent, and

Ring D is an optionally further substituted ring,

20 or a salt thereof.

2. The compound or salt according to claim 1, wherein, in the formula (I),

Ring A is a benzene ring;

25 Ring B is a benzene ring;

Ring C is an imidazole ring optionally further substituted by C₁₋₆ alkyl group(s);

L is a bond or a methylene group;

R¹ is

- (1) a hydrogen atom,
- (2) a halogen atom,
- (3) a mono- or di-C₁₋₆ alkylamino group,
- 5 (4) a 5- to 14-membered aromatic heterocyclic group, or
- (5) a 3- to 14-membered non-aromatic heterocyclic group optionally substituted by 1 to 3 C₁₋₆ alkyl groups; and

Ring D is

- (1) a benzene ring optionally further substituted by 1 to 3
- 10 substituents selected from
 - (a) a halogen atom,
 - (b) a hydroxy group,
 - (c) a C₁₋₆ alkyl group optionally substituted by 1 to 3 C₁₋₆ alkoxy groups,
 - 15 (d) a C₁₋₆ alkoxy group optionally substituted by 1 to 3 substituents selected from
 - (i) a carboxy group,
 - (ii) a C₁₋₆ alkoxy-carbonyl group,
 - (iii) a C₇₋₁₆ aralkyloxy-carbonyl group,
 - 20 (iv) a carbamoyl group optionally mono- or di-substituted by substituent(s) selected from
 - (I) C₁₋₆ alkyl group optionally substituted by 1 to 3 substituents selected from
 - (A) a C₃₋₁₀ cycloalkyl group,
 - 25 (B) a C₆₋₁₄ aryl group,
 - (C) a C₆₋₁₄ arylamino group optionally substituted by 1 to 3 halogen atoms,
 - (D) a 5- to 14-membered aromatic heterocyclic group,
 - 30 (E) a 3- to 14-membered non-aromatic heterocyclic group, and
 - (F) a carbamoyl group optionally mono- or di-substituted by substituent(s) selected from a C₁₋₆ alkyl group and a C₇₋₁₆ aralkyl group,
 - 35 (II) a C₂₋₆ alkenyl group optionally substituted by 1

to 3 C₆₋₁₄ aryl groups,
(III) a C₃₋₁₀ cycloalkyl group optionally substituted
by 1 to 3 C₁₋₆ alkyl groups,
(IV) a C₆₋₁₄ aryl group optionally substituted by 1 to
5 3 substituents selected from
(A) a halogen atom, and
(B) a C₁₋₆ alkyl group,
(V) a C₇₋₁₆ aralkyl group,
(VI) a 5- to 14-membered aromatic heterocyclic group,
10 and
(VII) a 3- to 14-membered non-aromatic heterocyclic
group, and
(v) a 3- to 14-membered non-aromatic
heterocyclylcarbonyl group optionally substituted by 1
15 to 3 substituents selected from
(I) a hydroxy group, and
(II) a C₁₋₆ alkyl group, and
(e) a C₇₋₁₆ aralkyloxy group,
(2) a cyclohexane ring,
20 (3) a pyridine ring,
(4) an isoxazole ring,
(5) a thiophene ring,
(6) a piperidine ring optionally further substituted by 1 to 3
C₁₋₆ alkoxy-carbonyl groups, or
25 (7) a tetrahydropyran ring.

3. N-(1,1-Dioxido-2,3-dihydro-1-benzothiophen-5-yl)-2-(4-(5-(1-
oxo-5-(piperidin-1-yl)-1,3-dihydro-2H-isoindol-2-yl)-1H-
benzimidazol-2-yl)phenoxy)acetamide, or a salt thereof.

30 4. 2-(2-(4-Bromophenyl)-1H-benzimidazol-5-yl)-5-(morpholin-4-
yl)isoindolin-1-one, or a salt thereof.

5. 5-(Piperidin-1-yl)-2-(2-(pyridin-3-yl)-1H-benzimidazol-5-
35 yl)isoindolin-1-one, or a salt thereof.

6. 5-(Piperidin-1-yl)-2-(2-(pyridin-4-yl)-1H-benzimidazol-5-yl)isoindolin-1-one, or a salt thereof.

5 7. 2-(2-(4-Hydroxyphenyl)-1H-benzimidazol-5-yl)-5-(piperidin-1-yl)isoindolin-1-one, or a salt thereof.

8. A cardiomyocyte maturation promoter comprising the compound or salt according to claim 1.

10

9. A method for preparing a mature cardiomyocyte, which comprises a step of culturing an immature cardiomyocyte in the presence of the compound or salt according to claim 1.